STAAR Surgical Swings to Loss Amid Rising Costs, Litigation
Ticker: STAA · Form: 10-Q · Filed: Aug 6, 2025 · CIK: 718937
| Field | Detail |
|---|---|
| Company | Staar Surgical Co (STAA) |
| Form Type | 10-Q |
| Filed Date | Aug 6, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Ophthalmic Goods, Net Loss, Revenue Growth, Cost Increases, Patent Litigation, Geographic Risk, Supplier Risk
TL;DR
**STAAR Surgical is bleeding cash, with a net loss despite revenue growth, making it a risky bet until they get costs under control.**
AI Summary
STAAR SURGICAL CO reported a net loss of $1.5 million for the three months ended June 27, 2025, a significant decline from a net income of $10.1 million in the prior-year period. Revenue for the three months ended June 27, 2025, was $82.5 million, compared to $81.0 million for the three months ended June 28, 2024, representing a modest 1.85% increase. The company's cost of sales increased to $21.9 million for the three months ended June 27, 2025, from $19.9 million in the prior-year period. Selling and marketing expenses also rose to $31.0 million from $27.9 million. A key business change includes the adoption of the 2024 Omnibus Incentive Plan on June 19, 2024, authorizing 2,000,000 shares for equity awards. A significant subsequent event is the settlement agreement with Alcon Research, LLC on August 4, 2025, resolving patent litigation, which could impact future financial results. The company faces geographic concentration risk, with sales in South Korea and Japan being notable, and supplier concentration risk, with a maximum of 10% of consolidated accounts payable attributable to a single supplier.
Why It Matters
STAAR Surgical's shift from profit to a $1.5 million net loss, despite a slight revenue increase, signals potential operational inefficiencies and increased cost pressures for investors. The settlement with Alcon Research, LLC, while resolving litigation, introduces uncertainty regarding its financial impact and competitive positioning in the ophthalmic goods market. For employees, this financial performance could influence future compensation and job security, especially with rising selling and marketing expenses. Customers might see impacts on product availability or pricing depending on how the company manages its cost structure and competitive landscape against rivals like Alcon.
Risk Assessment
Risk Level: high — The company reported a net loss of $1.5 million for the three months ended June 27, 2025, a substantial drop from a net income of $10.1 million in the prior-year period, indicating significant profitability challenges. Additionally, selling and marketing expenses increased to $31.0 million from $27.9 million, and cost of sales rose to $21.9 million from $19.9 million, demonstrating escalating operational costs that are eroding margins.
Analyst Insight
Investors should exercise caution and closely monitor STAAR Surgical's next earnings report for signs of cost containment and improved profitability. Consider holding off on new investments until there's clear evidence of a turnaround in net income and a detailed financial impact of the Alcon settlement.
Financial Highlights
- revenue
- $82.5 million
- net Income
- -$1.5 million
- revenue Growth
- +1.85%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Total Revenue | $82.5 million | +1.85% |
Key Numbers
- $1.5 million — Net Loss (for the three months ended June 27, 2025, compared to $10.1 million net income in prior year)
- $82.5 million — Revenue (for the three months ended June 27, 2025, a 1.85% increase from $81.0 million)
- $21.9 million — Cost of Sales (for the three months ended June 27, 2025, up from $19.9 million)
- $31.0 million — Selling and Marketing Expense (for the three months ended June 27, 2025, up from $27.9 million)
- 2,000,000 shares — Shares Authorized (under the 2024 Omnibus Incentive Plan adopted on June 19, 2024)
- 10% — Supplier Concentration Risk (maximum of consolidated accounts payable attributable to a single supplier)
Key Players & Entities
- STAAR SURGICAL CO (company) — filer of the 10-Q
- Alcon Research, LLC (company) — party in patent litigation settlement
- South Korea (country) — region with geographic concentration risk for sales
- Japan (country) — region with geographic concentration risk for sales
- Monrovia, CA (location) — business address of STAAR SURGICAL CO
FAQ
Why did STAAR Surgical Co. report a net loss in Q2 2025?
STAAR Surgical Co. reported a net loss of $1.5 million for the three months ended June 27, 2025, primarily due to increased cost of sales, which rose to $21.9 million from $19.9 million, and higher selling and marketing expenses, which increased to $31.0 million from $27.9 million.
What was STAAR Surgical's revenue for the second quarter of 2025?
STAAR Surgical's revenue for the three months ended June 27, 2025, was $82.5 million, showing a modest increase from $81.0 million reported for the three months ended June 28, 2024.
What is the significance of the Alcon Research, LLC settlement for STAAR Surgical?
The settlement agreement with Alcon Research, LLC on August 4, 2025, resolves patent litigation, which could reduce legal expenses and uncertainty for STAAR Surgical, but its specific financial impact on future results is yet to be fully disclosed.
What are the key risks identified in STAAR Surgical's 10-Q filing?
Key risks include geographic concentration risk, with significant sales in South Korea and Japan, and supplier concentration risk, where a maximum of 10% of consolidated accounts payable is attributable to a single supplier, potentially impacting supply chain stability.
How did STAAR Surgical's operating expenses change in Q2 2025?
Operating expenses for STAAR Surgical increased, with cost of sales rising to $21.9 million from $19.9 million and selling and marketing expenses increasing to $31.0 million from $27.9 million for the three months ended June 27, 2025, compared to the prior-year period.
What is the 2024 Omnibus Incentive Plan for STAAR Surgical?
The 2024 Omnibus Incentive Plan, adopted on June 19, 2024, authorizes the issuance of 2,000,000 shares of common stock for various equity awards, aiming to attract and retain key employees and align their interests with shareholders.
What should investors consider regarding STAAR Surgical's recent performance?
Investors should consider the shift to a net loss of $1.5 million despite revenue growth, indicating profitability challenges. The rising operating costs and the undisclosed financial impact of the Alcon settlement warrant careful evaluation before making investment decisions.
Where are STAAR Surgical's primary geographic sales concentrations?
STAAR Surgical has notable geographic sales concentrations in South Korea and Japan, which are highlighted as areas of geographic concentration risk in the filing.
When was the 10-Q filing for STAAR Surgical Co. submitted?
The 10-Q filing for STAAR Surgical Co. was filed on August 6, 2025, covering the period ended June 27, 2025.
How does STAAR Surgical manage its supplier risk?
STAAR Surgical manages supplier risk by ensuring that no single supplier accounts for more than 10% of its consolidated accounts payable, as stated in the filing, to mitigate dependence on any one vendor.
Risk Factors
- Patent Litigation Settlement [high — legal]: A settlement agreement with Alcon Research, LLC was reached on August 4, 2025, resolving patent litigation. The financial impact of this settlement on future results is yet to be fully determined but could be significant.
- Geographic Concentration [medium — operational]: The company faces significant geographic concentration risk, with notable sales in South Korea and Japan. Any adverse economic or political developments in these regions could disproportionately impact overall revenue.
- Supplier Concentration [low — operational]: There is a supplier concentration risk, with a maximum of 10% of consolidated accounts payable attributable to a single supplier. Disruption from this key supplier could impact production and supply chain.
Industry Context
STAAR Surgical operates in the ophthalmic goods industry, specifically focusing on intraocular lenses for refractive surgery. The market is competitive, with ongoing innovation in surgical techniques and implantable devices. Key trends include the increasing demand for vision correction procedures and advancements in lens technology.
Regulatory Implications
The company must comply with regulations related to medical devices in all operating regions. The settlement of patent litigation with Alcon Research, LLC, while resolving a legal dispute, highlights the importance of intellectual property management and potential future challenges in this area.
What Investors Should Do
- Monitor the impact of the Alcon settlement.
- Assess geographic revenue diversification.
- Analyze the impact of the new incentive plan.
Key Dates
- 2025-08-04: Settlement Agreement with Alcon Research, LLC — Resolves patent litigation, potentially impacting future financial performance and legal expenses.
- 2025-06-27: End of Second Quarter 2025 — Reporting period for the 10-Q, showing a net loss of $1.5 million and revenue of $82.5 million.
- 2024-06-19: Adoption of 2024 Omnibus Incentive Plan — Authorized 2,000,000 shares for equity awards, impacting future share dilution and executive compensation.
Glossary
- Omnibus Incentive Plan
- A plan that allows a company to grant various types of equity-based compensation, such as stock options, restricted stock, and performance shares, to employees and directors. (The company adopted a new plan authorizing 2,000,000 shares, which will affect future equity compensation and potential dilution.)
- Geographic Concentration Risk
- The risk that a company's financial performance is heavily reliant on a specific geographic region, making it vulnerable to local economic, political, or social events. (STAAR Surgical has notable sales in South Korea and Japan, exposing it to risks specific to these markets.)
- Supplier Concentration Risk
- The risk that a company relies heavily on a small number of suppliers, making it vulnerable to disruptions in supply if those suppliers face issues. (STAAR Surgical has a maximum of 10% of its accounts payable with any single supplier, indicating a degree of supplier dependency.)
Year-Over-Year Comparison
Compared to the prior-year period, STAAR SURGICAL CO experienced a significant shift from net income of $10.1 million to a net loss of $1.5 million for the three months ended June 27, 2025. While revenue saw a modest 1.85% increase to $82.5 million, both cost of sales and selling and marketing expenses rose, contributing to the decline in profitability. No new significant risks were explicitly detailed in the provided context, but the settlement of patent litigation is a key subsequent event that could influence future risk profiles.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding STAAR SURGICAL CO (STAA).